Details

Autor(en) / Beteiligte

• Okita, Kouki
• Okazaki, Shogo
• Uejima, Shinya
• Yamada, Erina
• Kaminaka, Hiroki
• Kondo, Misa
• Ueda, Shiho
• Tokiwa, Ryo
• Iwata, Nami
• Yamasaki, Akitaka
• Hayashi, Natsumi
• Ogura, Dai
• Hirotani, Kenji
• Yoshioka, Toshiaki
• Inoue, Masahiro
• Masuko, Kazue
• Masuko, Takashi

Titel

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

Ist Teil von

• Oncotarget, 2020-01, Vol.11 (1), p.31-45

Ort / Verlag

United States: Impact Journals LLC

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Resistance of progressive cancers against chemotherapy is a serious clinical problem. In this context, human epidermal growth factor receptor 3 (HER3) can play important roles in drug resistance to HER1- and HER2- targeted therapies. Since clinical testing of anti-HER3 monoclonal antibodies (mAbs) such as patritumab could not show remarkable effect compared with existing drugs, we generated novel mAbs against anti-HER3. Novel rat mAbs reacted with HEK293 cells expressing HER3, but not with cells expressing HER1, HER2 or HER4. Specificity of mAbs was substantiated by the loss of mAb binding with knockdown by siRNA and knockout of CRISPR/Cas9-based genome-editing. Analyses of CDR sequence and germline segment have revealed that seven mAbs are classified to four groups, and the binding of patritumab was inhibited by one of seven mAbs. Seven mAbs have shown reactivity with various human epithelial cancer cells, strong internalization activity of cell-surface HER3, and inhibition of NRG1 binding, NRG1-dependent HER3 phosphorylation and cell growth. Anti-HER3 mAbs were also reactive with tumor tissues and cancer tissue-originated spheroid. Ab4 inhibited tumor growth of human colon cancer cells in nude mice. Present mAbs may be superior to existing anti-HER3 mAbs and support existing anti-cancer therapeutic mAbs.